ADORNI, MARCO
ADORNI, MARCO
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Role of 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in malignant ovarian germ cell tumors: a single-center experience with long term follow-up
2019 Dolci, C; Ceppi, L; Guerra, L; Crivellaro, C; Lamanna, M; Adorni, M; Elisei, F; Bonazzi, C; Sina, F; Fruscio, R; Messa, C
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer
2020 Benvenuto, G; Todeschini, P; Paracchini, L; Calura, E; Fruscio, R; Romani, C; Beltrame, L; Martini, P; Ravaggi, A; Ceppi, L; Sales, G; Donati, F; Perego, P; Zanotti, L; Ballabio, S; Grassi, T; Marchette, M; Tognon, G; Sartori, E; Adorni, M; Odicino, F; D'Incalci, M; Bignotti, E; Romualdi, C; Marchini, S
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study
2020 Gadducci, A; Cosio, S; Lissoni, A; Zizioli, V; Adorni, M; Ferrero, A; Landoni, F; Sartori, E
Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
2021 Paracchini, L; Beltrame, L; Grassi, T; Inglesi, A; Fruscio, R; Landoni, F; Ippolito, D; Delle Marchette, M; Paderno, M; Adorni, M; Jaconi, M; Romualdi, C; D'Incalci, M; Siravegna, G; Marchini, S
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers
2021 Ceppi, L; Grassi, T; Galli, F; Buda, A; Aletti, G; Lissoni, A; Adorni, M; Garbi, A; Colombo, N; Bonazzi, C; Landoni, F; Fruscio, R
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience
2022 Adorni, M; Bazzurini, L; Lissoni, A; Vecchione, F; Negri, S; Grassi, T; Buda, A; Landoni, F